logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Age and severe adverse drug reactions caused by nifedipine and verapamil.

    Article - En anglais

    The association of age with risk for severe adverse drug reactions (SADRs) was studied in 2371 and 862 hospitalized patients taking nifedipine and verapamil, respectively.

    Nifedipine caused hypotension (n=22), tachycardia (n=3), and acute renal failure (n=1) (total SADR rate, 1.1%, 26/2371).

    Verapamil caused hypotension (n=3), bradycardia (n=9), and atrioventricular blocks (n=2) (total SADR rate, 1.6%, 14/862).

    The mean age of patients with and without SADRs was for nifedipine 77.1 ± 1.7 and 71.8 ± 0.8 years, respectively (p<0.05), and for verapamil 73.4 ± 2.9 and 73.1 ± 0.4 years, respectively.

    Sex, length of stay, comorbidity, polypharmacy, intake of slow-release preparations, daily dosage, and new intake of calcium antagonists were examined as potential confounders of the age-SADR association.

    After adjusting for potential confounders, age was signficantly and independently associated with SADRs caused by nifedipine, but not with SADRs caused by verapamil (OR=1.69,95% CI=1.05-2.72 and OR=1.06,95% CI=0.63-1.68 for 10-year increase, respectively).

    Although nifedipine and verapamil did not have significantly different rates of SADRs, an age-related gradient was found only for nifedipine.

    Mots-clés Pascal : Nifédipine, Vérapamil, Antagoniste calcium, Toxicité, Epidémiologie, Age, Homme, Hôpital, Italie, Europe, Pharmacovigilance, Dihydropyridine dérivé, Aralkylamine

    Mots-clés Pascal anglais : Calcium antagonist, Toxicity, Epidemiology, Age, Human, Hospital, Italy, Europe, Pharmacovigilance, Dihydropyridine derivative

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0461688

    Code Inist : 002B02U10. Création : 10/04/1997.